Amino acid Metabolism Disorders Treatment Market By Indication (Phenylketonuria, Maple syrup urine disease, Citrullinemia, Homocystinuria, Argininosuccinic aciduria), By Product (Folic Acid, Vitamin B6 and B12, Arginine, Thiamine, Betaine, Sapropterin, Others), By Distribution channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global amino acid metabolism disorders treatment market was valued at $630.92 million in 2021, and is projected to reach $961.75 million by 2031, registering a CAGR of 4.3% from 2022 to 2031.
Metabolism is the process in which complex proteins and carbohydrates are break down into sugar and acids, which serve as body fuel. When something goes wrong with the metabolism process, it causes metabolic disorders. One group of among these disorders is amino acid metabolism disorder. They are also called as “building blocks” of the body. The amino acid metabolism disorders arises due to impairment in synthesis and degradation of amino acids. These problem leads to build up of harmful and toxic substances in the body, which causes life-threatening, health problems. The group of amino acid metabolism disorders include maple syrup urine disease, phenylketonuria, homocystinuria, and citrullinemia. Furthermore, the treatments for amino acid metabolism disorders include vitamin supplements, medications, and special diets.
The growth of amino acid metabolism disorders treatment market is majorly driven by increase in prevalence of amino acid metabolism disorders such as maple syrup urine disease, phenylketonuria, and citrullinemia high cost of treatments, rising research and development activities on amino acid metabolism disorders treatment, increased disposable income in developing countries and development of healthcare infrastructure. However, increase in cost of amino acid supplement, lack of awareness of amino acid metabolism disorders and associated side effects of phenylketonuria injections impacts the growth of the market. Conversely, increase in the healthcare expenditure provides lucrative opportunities for the market.
The amino acid metabolism disorders treatment market is segmented into product type, indication, distribution channel, and region. By product type, the market is categorized into folic acid, Vitamin B6 and B12, arginine, thiamine, betaine, sapropterin, and others. On the basis of indication, the market is categorized into phenylketonuria, maple syrup urine disease, citrullinemia, homocystinuria, and argininosuccinic aciduria. Based on distribution channel, the market is categorized into hospital pharmacies, drug stores and retail pharmacies, and online providers. The drug stores and retail pharmacies segment is further subcategorized as prescription drug and OTC drug. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa and rest of LAMEA).
Major key players that operate in the global amino acid metabolism disorders treatment market are Amino GmbH, Biogen Idec, Biomarin Pharmaceuticals, Inc., GlaxoSmithKline Plc, Koninklijke DSM N.V., Merck KGaA, Pfizer, Inc., Pharmavite, Recordati S.p.A., Sanofi, Shine Star (Hubei) Biological Engineering Co., Ltd., and Teva Pharmaceutical Industries Ltd.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the amino acid metabolism disorders treatment market analysis from 2021 to 2031 to identify the prevailing amino acid metabolism disorders treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the amino acid metabolism disorders treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global amino acid metabolism disorders treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Indication
Phenylketonuria
Maple syrup urine disease
Citrullinemia
Homocystinuria
Argininosuccinic aciduria
By Product
Folic Acid
Vitamin B6 and B12
Arginine
Thiamine
Betaine
Sapropterin
Others
By Distribution channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Prescription type
Prescription drug
OTC drug
Online Providers
By Region
North America
Canada
Mexico
U.S.
Europe
Germany
France
UK
Italy
Spain
Rest Of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest Of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest Of LAMEA
Key Market Players
AMINO GmbH
Civentichem, LLC, Ltd.
GlaxoSmithKline PLC
Koninklijke DSM N.V.
Kyowa Hakko Kirin Co., Ltd.
Merck KGaA
Pfizer, Inc.
Recordati S.p.A.
Sanofi
Shine Star (Hubei) Biological Engineering Co.
BioMarin Pharmaceutical Inc.
Teva Pharmaceutical Industries Ltd.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Phenylketonuria
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Maple syrup urine disease
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Citrullinemia
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Homocystinuria
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- 4.6 Argininosuccinic aciduria
- 4.6.1 Key market trends, growth factors and opportunities
- 4.6.2 Market size and forecast, by region
- 4.6.3 Market analysis by country
- CHAPTER 5: AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Folic Acid
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Vitamin B6 and B12
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Arginine
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.5 Thiamine
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
- 5.6 Betaine
- 5.6.1 Key market trends, growth factors and opportunities
- 5.6.2 Market size and forecast, by region
- 5.6.3 Market analysis by country
- 5.7 Sapropterin
- 5.7.1 Key market trends, growth factors and opportunities
- 5.7.2 Market size and forecast, by region
- 5.7.3 Market analysis by country
- 5.8 Others
- 5.8.1 Key market trends, growth factors and opportunities
- 5.8.2 Market size and forecast, by region
- 5.8.3 Market analysis by country
- CHAPTER 6: AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospital Pharmacies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Drug Stores and Retail Pharmacies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.3.4 Drug Stores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
- 6.3.4.1 Prescription drug Market size and forecast, by region
- 6.3.4.2 OTC drug Market size and forecast, by region
- 6.4 Online Providers
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- CHAPTER 7: AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Indication
- 7.2.3 North America Market size and forecast, by Product
- 7.2.4 North America Market size and forecast, by Distribution channel
- 7.2.4.1 North America Drug Stores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Indication
- 7.2.5.1.2 Market size and forecast, by Product
- 7.2.5.1.3 Market size and forecast, by Distribution channel
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Indication
- 7.2.5.2.2 Market size and forecast, by Product
- 7.2.5.2.3 Market size and forecast, by Distribution channel
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Indication
- 7.2.5.3.2 Market size and forecast, by Product
- 7.2.5.3.3 Market size and forecast, by Distribution channel
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Indication
- 7.3.3 Europe Market size and forecast, by Product
- 7.3.4 Europe Market size and forecast, by Distribution channel
- 7.3.4.1 Europe Drug Stores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Indication
- 7.3.5.1.2 Market size and forecast, by Product
- 7.3.5.1.3 Market size and forecast, by Distribution channel
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Indication
- 7.3.5.2.2 Market size and forecast, by Product
- 7.3.5.2.3 Market size and forecast, by Distribution channel
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Indication
- 7.3.5.3.2 Market size and forecast, by Product
- 7.3.5.3.3 Market size and forecast, by Distribution channel
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Indication
- 7.3.5.4.2 Market size and forecast, by Product
- 7.3.5.4.3 Market size and forecast, by Distribution channel
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Indication
- 7.3.5.5.2 Market size and forecast, by Product
- 7.3.5.5.3 Market size and forecast, by Distribution channel
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Indication
- 7.3.5.6.2 Market size and forecast, by Product
- 7.3.5.6.3 Market size and forecast, by Distribution channel
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Indication
- 7.4.3 Asia-Pacific Market size and forecast, by Product
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution channel
- 7.4.4.1 Asia-Pacific Drug Stores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Indication
- 7.4.5.1.2 Market size and forecast, by Product
- 7.4.5.1.3 Market size and forecast, by Distribution channel
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Indication
- 7.4.5.2.2 Market size and forecast, by Product
- 7.4.5.2.3 Market size and forecast, by Distribution channel
- 7.4.5.3 Australia
- 7.4.5.3.1 Market size and forecast, by Indication
- 7.4.5.3.2 Market size and forecast, by Product
- 7.4.5.3.3 Market size and forecast, by Distribution channel
- 7.4.5.4 India
- 7.4.5.4.1 Market size and forecast, by Indication
- 7.4.5.4.2 Market size and forecast, by Product
- 7.4.5.4.3 Market size and forecast, by Distribution channel
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Indication
- 7.4.5.5.2 Market size and forecast, by Product
- 7.4.5.5.3 Market size and forecast, by Distribution channel
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Indication
- 7.4.5.6.2 Market size and forecast, by Product
- 7.4.5.6.3 Market size and forecast, by Distribution channel
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Indication
- 7.5.3 LAMEA Market size and forecast, by Product
- 7.5.4 LAMEA Market size and forecast, by Distribution channel
- 7.5.4.1 LAMEA Drug Stores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Indication
- 7.5.5.1.2 Market size and forecast, by Product
- 7.5.5.1.3 Market size and forecast, by Distribution channel
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Indication
- 7.5.5.2.2 Market size and forecast, by Product
- 7.5.5.2.3 Market size and forecast, by Distribution channel
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Indication
- 7.5.5.3.2 Market size and forecast, by Product
- 7.5.5.3.3 Market size and forecast, by Distribution channel
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Indication
- 7.5.5.4.2 Market size and forecast, by Product
- 7.5.5.4.3 Market size and forecast, by Distribution channel
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 AMINO GmbH
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Civentichem, LLC, Ltd.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 GlaxoSmithKline PLC
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Koninklijke DSM N.V.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Kyowa Hakko Kirin Co., Ltd.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Merck KGaA
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Pfizer, Inc.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Recordati S.p.A.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Sanofi
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Shine Star (Hubei) Biological Engineering Co.
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- 9.11 BioMarin Pharmaceutical Inc.
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
- 9.12 Teva Pharmaceutical Industries Ltd.
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 2. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR PHENYLKETONURIA, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR PHENYLKETONURIA, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR MAPLE SYRUP URINE DISEASE, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR MAPLE SYRUP URINE DISEASE, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR CITRULLINEMIA, BY REGION, 2021-2031 ($MILLION)
- TABLE 7. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR CITRULLINEMIA, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 8. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR HOMOCYSTINURIA, BY REGION, 2021-2031 ($MILLION)
- TABLE 9. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR HOMOCYSTINURIA, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 10. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR ARGININOSUCCINIC ACIDURIA, BY REGION, 2021-2031 ($MILLION)
- TABLE 11. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR ARGININOSUCCINIC ACIDURIA, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 12. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 13. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR FOLIC ACID, BY REGION, 2021-2031 ($MILLION)
- TABLE 14. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR FOLIC ACID, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 15. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR VITAMIN B6 AND B12, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR VITAMIN B6 AND B12, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 17. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR ARGININE, BY REGION, 2021-2031 ($MILLION)
- TABLE 18. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR ARGININE, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 19. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR THIAMINE, BY REGION, 2021-2031 ($MILLION)
- TABLE 20. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR THIAMINE, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 21. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR BETAINE, BY REGION, 2021-2031 ($MILLION)
- TABLE 22. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR BETAINE, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 23. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR SAPROPTERIN, BY REGION, 2021-2031 ($MILLION)
- TABLE 24. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR SAPROPTERIN, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 25. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 26. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 27. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 28. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 29. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 30. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 31. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 32. GLOBAL DRUG STORES AND RETAIL PHARMACIES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
- TABLE 33. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR PRESCRIPTION DRUG, BY REGION, 2021-2031 ($MILLION)
- TABLE 34. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR OTC DRUG, BY REGION, 2021-2031 ($MILLION)
- TABLE 35. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 36. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 37. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 38. NORTH AMERICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 39. NORTH AMERICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 40. NORTH AMERICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 41. NORTH AMERICA DRUG STORES AND RETAIL PHARMACIES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
- TABLE 42. NORTH AMERICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 43. U.S. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 44. U.S. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 45. U.S. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 46. CANADA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 47. CANADA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 48. CANADA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 49. MEXICO AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 50. MEXICO AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 51. MEXICO AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 52. EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 53. EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 54. EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 55. EUROPE DRUG STORES AND RETAIL PHARMACIES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
- TABLE 56. EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 57. GERMANY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 58. GERMANY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 59. GERMANY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 60. FRANCE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 61. FRANCE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 62. FRANCE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 63. UK AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 64. UK AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 65. UK AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 66. ITALY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 67. ITALY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 68. ITALY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 69. SPAIN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 70. SPAIN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 71. SPAIN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 72. REST OF EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 73. REST OF EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 74. REST OF EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 75. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 76. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 77. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 78. ASIA-PACIFIC DRUG STORES AND RETAIL PHARMACIES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
- TABLE 79. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 80. JAPAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 81. JAPAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 82. JAPAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 83. CHINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 84. CHINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 85. CHINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 86. AUSTRALIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 87. AUSTRALIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 88. AUSTRALIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 89. INDIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 90. INDIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 91. INDIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 92. SOUTH KOREA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 93. SOUTH KOREA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 94. SOUTH KOREA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 95. REST OF ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 96. REST OF ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 97. REST OF ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 98. LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 99. LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 100. LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 101. LAMEA DRUG STORES AND RETAIL PHARMACIES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
- TABLE 102. LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 103. BRAZIL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 104. BRAZIL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 105. BRAZIL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 106. SAUDI ARABIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 107. SAUDI ARABIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 108. SAUDI ARABIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 109. SOUTH AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 110. SOUTH AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 111. SOUTH AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 112. REST OF LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 113. REST OF LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 114. REST OF LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 115.AMINO GMBH: COMPANY SNAPSHOT
- TABLE 116.AMINO GMBH: OPERATING SEGMENTS
- TABLE 117.AMINO GMBH: PRODUCT PORTFOLIO
- TABLE 118.AMINO GMBH: NET SALES,
- TABLE 119.AMINO GMBH: KEY STRATERGIES
- TABLE 120.CIVENTICHEM, LLC, LTD.: COMPANY SNAPSHOT
- TABLE 121.CIVENTICHEM, LLC, LTD.: OPERATING SEGMENTS
- TABLE 122.CIVENTICHEM, LLC, LTD.: PRODUCT PORTFOLIO
- TABLE 123.CIVENTICHEM, LLC, LTD.: NET SALES,
- TABLE 124.CIVENTICHEM, LLC, LTD.: KEY STRATERGIES
- TABLE 125.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
- TABLE 126.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
- TABLE 127.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
- TABLE 128.GLAXOSMITHKLINE PLC: NET SALES,
- TABLE 129.GLAXOSMITHKLINE PLC: KEY STRATERGIES
- TABLE 130.KONINKLIJKE DSM N.V.: COMPANY SNAPSHOT
- TABLE 131.KONINKLIJKE DSM N.V.: OPERATING SEGMENTS
- TABLE 132.KONINKLIJKE DSM N.V.: PRODUCT PORTFOLIO
- TABLE 133.KONINKLIJKE DSM N.V.: NET SALES,
- TABLE 134.KONINKLIJKE DSM N.V.: KEY STRATERGIES
- TABLE 135.KYOWA HAKKO KIRIN CO., LTD.: COMPANY SNAPSHOT
- TABLE 136.KYOWA HAKKO KIRIN CO., LTD.: OPERATING SEGMENTS
- TABLE 137.KYOWA HAKKO KIRIN CO., LTD.: PRODUCT PORTFOLIO
- TABLE 138.KYOWA HAKKO KIRIN CO., LTD.: NET SALES,
- TABLE 139.KYOWA HAKKO KIRIN CO., LTD.: KEY STRATERGIES
- TABLE 140.MERCK KGAA: COMPANY SNAPSHOT
- TABLE 141.MERCK KGAA: OPERATING SEGMENTS
- TABLE 142.MERCK KGAA: PRODUCT PORTFOLIO
- TABLE 143.MERCK KGAA: NET SALES,
- TABLE 144.MERCK KGAA: KEY STRATERGIES
- TABLE 145.PFIZER, INC.: COMPANY SNAPSHOT
- TABLE 146.PFIZER, INC.: OPERATING SEGMENTS
- TABLE 147.PFIZER, INC.: PRODUCT PORTFOLIO
- TABLE 148.PFIZER, INC.: NET SALES,
- TABLE 149.PFIZER, INC.: KEY STRATERGIES
- TABLE 150.RECORDATI S.P.A.: COMPANY SNAPSHOT
- TABLE 151.RECORDATI S.P.A.: OPERATING SEGMENTS
- TABLE 152.RECORDATI S.P.A.: PRODUCT PORTFOLIO
- TABLE 153.RECORDATI S.P.A.: NET SALES,
- TABLE 154.RECORDATI S.P.A.: KEY STRATERGIES
- TABLE 155.SANOFI: COMPANY SNAPSHOT
- TABLE 156.SANOFI: OPERATING SEGMENTS
- TABLE 157.SANOFI: PRODUCT PORTFOLIO
- TABLE 158.SANOFI: NET SALES,
- TABLE 159.SANOFI: KEY STRATERGIES
- TABLE 160.SHINE STAR (HUBEI) BIOLOGICAL ENGINEERING CO.: COMPANY SNAPSHOT
- TABLE 161.SHINE STAR (HUBEI) BIOLOGICAL ENGINEERING CO.: OPERATING SEGMENTS
- TABLE 162.SHINE STAR (HUBEI) BIOLOGICAL ENGINEERING CO.: PRODUCT PORTFOLIO
- TABLE 163.SHINE STAR (HUBEI) BIOLOGICAL ENGINEERING CO.: NET SALES,
- TABLE 164.SHINE STAR (HUBEI) BIOLOGICAL ENGINEERING CO.: KEY STRATERGIES
- TABLE 165.BIOMARIN PHARMACEUTICAL INC.: COMPANY SNAPSHOT
- TABLE 166.BIOMARIN PHARMACEUTICAL INC.: OPERATING SEGMENTS
- TABLE 167.BIOMARIN PHARMACEUTICAL INC.: PRODUCT PORTFOLIO
- TABLE 168.BIOMARIN PHARMACEUTICAL INC.: NET SALES,
- TABLE 169.BIOMARIN PHARMACEUTICAL INC.: KEY STRATERGIES
- TABLE 170.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 171.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
- TABLE 172.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 173.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
- TABLE 174.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SEGMENTATION
- FIGURE 2.AMINO ACID METABOLISM DISORDERS TREATMENT MARKET,2021-2031
- FIGURE 3.AMINO ACID METABOLISM DISORDERS TREATMENT MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.AMINO ACID METABOLISM DISORDERS TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.AMINO ACID METABOLISM DISORDERS TREATMENT MARKET,BY INDICATION,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF PHENYLKETONURIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF MAPLE SYRUP URINE DISEASE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET,2021-2031(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF CITRULLINEMIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET,2021-2031(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF HOMOCYSTINURIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET,2021-2031(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ARGININOSUCCINIC ACIDURIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET,2021-2031(%)
- FIGURE 18.AMINO ACID METABOLISM DISORDERS TREATMENT MARKET,BY PRODUCT,2021(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF FOLIC ACID AMINO ACID METABOLISM DISORDERS TREATMENT MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF VITAMIN B6 AND B12 AMINO ACID METABOLISM DISORDERS TREATMENT MARKET,2021-2031(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ARGININE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET,2021-2031(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF THIAMINE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET,2021-2031(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF BETAINE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET,2021-2031(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF SAPROPTERIN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET,2021-2031(%)
- FIGURE 25.COMPARATIVE SHARE ANALYSIS OF OTHERS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET,2021-2031(%)
- FIG
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook